Hepion Pharmaceuticals (NASDAQ:HEPA) has jumped 46% after hours after it posted positive lab data for its drug candidate for treating liver disease nonalcoholic steatohepatitis (NASH).
An expanded study with human precision cut liver
slices shows that CRV431 prevented experimentally induced liver fibrosis
to a greater extent than four other NASH drug candidates (obeticholic
acid, elafibranor, resmetirom and Aramchol).
A Phase 1, single ascending dose study previously
showed CRV431 to be safe and well tolerated in humans. Currently, CRV431
is being administered to humans in a 28-day multiple ascending dose
study.
https://seekingalpha.com/news/3535512-hepion-pharmaplus-46-on-positive-nash-data
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.